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Abstract
Introduction: Advanced glycation endproducts (AGEs) may be involved in the development of atherosclerosis, beyond
diabetes and renal disease. Skin autofluorescence (AF) is a non-invasive marker for AGEs. We examined whether skin AF is
increased in (subclinical) atherosclerosis and associated with the degree of atherosclerosis independent of diabetes and
renal function.
Methods: A cross-sectional study of 223 patients referred for primary (n= 163) or secondary (n= 60) prevention between
2006 and 2012 was performed. Skin AF was measured using the AGE-Reader. Ultrasonography was used to assess plaques in
carotid and femoral arteries and computed tomography for the calculation of the coronary artery calcium score (CACS; in
primary prevention only). Primary prevention patients were divided into a group with subclinical atherosclerosis defined as
.1 plaque or CACS.100 (n= 67; age 53 year [interquartile range 48–56]; 49% male) and without (controls; 96; 43 [38–51];
55%). Secondary prevention were patients with peripheral arterial disease (60; 64 [58–70]; 73%).
Results: Skin AF was higher in subclinical and clinical atherosclerosis compared with controls (skin AF 2.11 [interquartile
range 1.83–2.46] and 2.71 [2.15–3.27] vs. 1.87 [1.68–2.12] respectively; P= 0.005 and ,0.001). In a multivariate analysis, the
association of skin AF with the atherosclerosis categories was independent of age, sex, diabetes, presence of the metabolic
syndrome, Framingham Risk Score, and renal function. Skin AF correlated with most cardiovascular risk factors, Framingham
risk score, and IMT and CACS.
Conclusions: Skin AF is increased in documented subclinical and clinical atherosclerosis, independent of known risk factors
such as diabetes and renal disease. These data suggest that AGEs may be associated with the burden of atherosclerosis and
warrant a prospective study to investigate its clinical usability as a risk assessment tool for primary prevention.
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Introduction
Atherosclerosis is characterized by chronic low grade inflam-
mation and oxidative stress leading to plaque formation and
ultimately calcification. [1] While formerly only implicated in
diabetes and renal disease, evidence for an important role of
advanced glycation endproducts (AGEs) in cardiovascular disease
(CVD) beyond these conditions is growing. [2] AGEs are formed
by non-enzymatic glycation and oxidative reactions leading to
stable structures accumulating on long-lived proteins. They
promote cellular stress responses by engagement of the receptor
for AGEs (RAGE). AGE epitopes have been detected in human
plaques. [3] Lowering AGEs or blocking RAGE in murine models
has been found to attenuate plaque formation, supporting the
involvement of AGEs in atherosclerosis [3,4].
Measurement of tissue AGEs may be preferable over plasma
measurement, since long-lived proteins accumulate in the tissues in
which chronic complications develop. [5] Thus, blood and urine
AGEs do not necessarily reflect their tissue levels. [6] We
developed and validated a non-invasive technique to quantify
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tissue AGEs by measuring skin autofluorescence (AF). [7,8] It has
been validated with skin biopsies in patients with diabetes or renal
disease and healthy controls [7–9] and was shown to correlate
strongly with plasma circulating AGEs and with corneal and lens
fluorescence in type 1 diabetes. [10] Skin AF is elevated in diabetes
mellitus and end-stage renal disease and is associated with
cardiovascular mortality, independent of known CVD risk factors.
[8,11] Skin AF is also elevated in coronary artery disease, [12,13]
correlates with carotid intima media thickness (IMT), [14] and is
elevated in patients with carotid artery stenosis and peripheral
artery disease (PAD), [15,16] irrespective of diabetes or renal
disease.
Atherosclerosis is a generalized disease that develops years
before clinical events occur. Previous studies have only focused on
symptomatic disease in a single vascular bed (coronary, carotid, or
femoral). It is yet unclear whether skin AF is already increased in
subjects with subclinical atherosclerosis. We hypothesized that skin
AF is increased in patients with subclinical atherosclerosis,
independent of diabetes and renal function, and that skin AF is
positively associated with the degree of atherosclerosis. Therefore,
we compared skin AF in subjects without and with subclinical
atherosclerosis as ascertained by non-invasive imaging measures,
and in patients with clinically overt and established atherosclerosis.
Materials and Methods
Patients
We performed a cross-sectional study of 223 patients, at least 18
years of age, visiting the outpatient vascular clinic of our hospital
for primary (n=163) or secondary (n=60) cardiovascular preven-
tion between 2006 and 2012. The study was approved by the local
institutional review board at the University Medical Center
Groningen and all participants gave written informed consent.
Eligible patients of the primary prevention group were referred for
counselling because of an increased CVD risk based on
conventional cardiovascular risk factors and did not have a history
of CVD or symptoms of coronary artery disease, cerebrovascular
disease or PAD. The primary prevention group was divided in
patients with and without evidence of subclinical atherosclerosis,
the latter forming the control group. Subclinical atherosclerosis
was defined as the presence of one or more plaques in carotid and
femoral arteries using high resolution ultrasonography or a
coronary artery calcium score (CACS) .100 on computed
tomography (CT). These cut-offs were chosen on the basis of
previous reports showing that subjects meeting these criteria are at
substantially increased CVD risk. [17,18] The secondary preven-
tion group consisted of patients with proven PAD, which was
ascertained by a resting ankle-brachial index #0.90 or a toe-
brachial index #0.70 if possible in case of non-compressible calf
arteries, or a history of radiological or surgical intervention for
PAD. PAD was confirmed by CT angiography, magnetic
resonance angiography or catheter angiography. For both primary
and secondary prevention, exclusion criteria consisted of an
estimated glomerular filtration rate of ,60 mL/min/1.73 m2, a
history of renal transplantation, a recent acute coronary syndrome
or cerebrovascular attack, or sepsis (all within the past 3 months),
cognitive impairment, or current cancer or autoimmune disease
because these conditions have previously been shown to increase
skin AF. Furthermore, those with a brown or black skin
(Fitzpatrick type V skin) were excluded because skin AF could
not be reliably measured with the device used in the current study
due to excessive light absorption in this skin type. In the primary
and secondary prevention group, skin AF and CACS measure-
ments were performed. Since the secondary prevention group of
PAD patients by definition had clinically established and proven
atherosclerotic disease, no ultrasonographic plaque scoring was
performed in this group.
Risk Factor Assessment
The following risk factors were assessed: smoking status,
dyslipidaemia (fasting low density lipoprotein (LDL) cholesterol
.4.0 mmol/l, high density lipoprotein (HDL) cholesterol
,1.2 mmol/L (female) or HDL-cholesterol ,1.0 mmol/L (male),
triglycerides .4.0 mmol/L, or current lipid lowering treatment),
hypertension (blood pressure $140/90 mmHg or drug treatment
for hypertension), obesity (body mass index (BMI) $30 kg/m2),
family history of premature CVD (in first degree relatives, male
,55 years and female ,65 years), and diabetes mellitus (known
diabetes, fasting plasma glucose .7.0 mmol/l or random plasma
glucose .11.1 mmol/L). Medication use was documented and
additional measurements of serum creatinine and high-sensitive C-
reactive protein (hsCRP) were performed. Metabolic syndrome
was defined according to the International Diabetes Federation, in
which BMI substituted waist circumference, because the latter was
unavailable. [19] Framingham risk score was defined as the
10 year risk of coronary heart disease (i.e. myocardial infarction or
death from coronary heart disease). [20] Kidney function was
estimated using the MDRD formula [21].
Measurement of Skin Autofluorescence
Skin AF was assessed using the AGE Reader (DiagnOptics
Technologies BV, Groningen, the Netherlands). This is a non-
invasive desk-top device that uses the characteristic fluorescent
properties of certain AGEs to estimate the level of AGEs
accumulation in the skin. The method has been extensively
validated and strongly correlates with individual AGE compounds
measured in skin biopsy dermal tissue homogenates taken from the
same site as skin AF measurement. [22] Technical details
concerning the optical technique have been described elsewhere.
[7] In short, the right forearm was positioned on top of the device
which is the standard and most practical measuring site for skin
AF. The AGE Reader illuminates a skin surface of 4 cm2 with an
excitation light source with a peak excitation of 370 nm. Emission
light (fluorescence in the wavelength of 420–600 nm) and reflected
excitation light (with a wavelength of 300–420 nm) from the skin is
measured with a spectrometer. Skin AF is calculated as the ratio
between the emission light and reflected excitation light, multiplied
by 100 and expressed in arbitrary units. A series of three
consecutive measurements was carried out, taking less than a
minute of time. Mean skin AF was calculated from these three
consecutive measurements and used in the analyses. The method
is observer independent and has an intra-patient coefficient of
variation of 5% [7].
Plaque Assessment by Intima Media Thickness
Plaque assessment was performed by measurement of carotid
and femoral IMT, as described previously. [23] High resolution B-
mode ultrasonography (Acuson 128XP10, Acuson Corporation,
Mountainview, USA) with a 7 MHz linear array transducer was
used with the subject in a supine position. For both carotid
arteries, a mean value over 10 mm length of the far wall segments
of the common and internal carotid artery and the carotid bulb
were imaged from a fixed lateral transducer position. The same
procedure was used for the femoral arteries, with measurement of
segments of the common femoral artery and the superficial
femoral artery. Mean and maximum IMT of each of the 10
segments was calculated. Presence of a plaque was based on the
Mannheim consensus statement. A plaque is defined as a focal
Skin Autofluorescence and Atherosclerosis
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structure that encroaches onto the arterial lumen at least 0.5 mm
or 50% of the surrounding IMT value or demonstrates a thickness
of $1.5 mm as measured from the media-adventitia interface to
the intima-lumen interface. [24] A total plaque score was
calculated summing all segments with presence of at least one
plaque, consequently ranging from 0 to 10. The sonographers
were unaware of the risk factors of the studied persons. The
measurements were analyzed offline by an independent image
analyst who also was unaware of the clinical status of the patient.
Measurement of Coronary Calcium Score
CACS was measured either with electron beam CT (C-150
Imatron, San Francisco, USA) or dual-source CT (Siemens
Somatom Definition, Forchheim, Germany). A standard scanning
protocol was applied. The scan range was from the carina to
1.5 cm below the base of the heart. Images were acquired at 80%
of the cardiac cycle for electron beam CT or 70% for dual-source
CT, with electrocardiographic triggering, during a single breath-
hold. For electron beam CT 38 contiguous, 3 mm thick slices were
obtained, with a scan time of 100 ms per slice. Tube voltage was
120 kV, with a tube current of 64 mA and a field-of-view of
260 mm. For dual-source CT a sequential scanning protocol was
used, with 663 mm collimation, 330 ms rotation time, tube
voltage 120 kV, tube current dependent on the weight of the
patient and a field-of-view of 250 mm. Quantification of CACS
was performed with the use of dedicated software (AccuImage
Diagnostics Corporation, South San Francisco, USA for electron
beam CT, and Siemens Syngo, Forchheim, Germany for dual-
source CT) by trained readers, according to the method described
by Agatston. [25] The CACS of the dual-source CT was corrected
to correlate better with the values of the reference standard,
electron beam CT [26].
Laboratory Analyses
Venous blood samples were collected into EDTA-containing
tubes (1.5 mg/mL). Plasma cholesterol and triglycerides were
assayed by routine enzymatic methods (Roche Diagnostics GmbH,
Mannheim, Germany). HDL-cholesterol was measured with a
homogeneous enzymatic colorimetric test (Roche/Hitachi).
HsCRP was determined by nephelometry with a lower limit of
0.175 mg/L (BNII N; Dade Behring, Marburg, Germany).
Glucose was measured with an APEC glucose analyzer (APEC
Inc., Danvers, MA, USA).
Statistical Analysis
Based on previous studies in asymptomatic subjects, we
expected a standard deviation of 0.3 for skin AF and considered
a mean difference of 0.2 arbitrary units (AU) between patients with
subclinical and those without subclinical atherosclerosis as
clinically relevant. With a power of 80% and an alpha of 0.05
and under the assumption of normality, at least 36 subjects were
needed to reject the null hypothesis of no difference in a 2-sided
independent t-test.
Normally distributed parameters are shown as mean with
standard deviation, non-normally distributed values are given as
median (interquartile range) and categorical variables are reported
as number (percentage). To investigate differences between the
three risk groups, the Kruskal-Wallis test for continuous variables
and the Chi-square test for categorical variables was used. In case
of a significant difference between the three groups, the Mann-
Whitney U test was used to compare the subclinical atherosclerosis
group with the control group. Several ordinal logistic regression
models were developed to examine the relationship between the
atherosclerosis groups and skin AF in addition to other risk factors.
In the first model, age, sex, diabetes mellitus and renal function
were entered as covariates and in the second model, cardiovas-
cular risk factors defined in the Framingham risk score were added
to the first model. In the third model, age, sex, renal function and
metabolic syndrome were entered. The odds ratio of increasing
level of atherosclerosis (control, subclinical, clinical atherosclerosis)
was calculated for each AU increase in skin AF.
The Spearman correlation coefficient was used to examine the
univariate association between skin AF and other factors. Those
with a P,0.10 were included in the linear multiple regression
model using stepwise selection of variables. All statistical analyses
were performed using PASW Statistics version 18.0.3 (SPSS Inc,
Chicago, Illinois, USA). All statistical tests are two-sided. A P-value
of less than 0.05 was considered statistically significant.
Results
Patients
A total of 223 patients participated. Characteristics are shown in
Table 1, 2 and 3. In the primary prevention group, 67 subjects had
subclinical atherosclerosis, while 96 subjects did not meet our
criteria for subclinical atherosclerosis and were assigned to the
control group. Age, sex, BMI, systolic blood pressure, fasting
glucose, hsCRP, lipids, kidney function, the presence of diabetes
mellitus, smoking status, hypertension, and cardiovascular drug
use differed significantly between groups. Subjects of the
subclinical atherosclerosis group were older, had a higher BMI,
systolic blood pressure, and fasting glucose levels as compared with
the control group. As expected from their need for secondary
prevention, PAD patients used statins more frequently, and
consequently had lower lipid levels.
Skin Autofluorescence
Skin AF was significantly higher in patients with subclinical
atherosclerosis and PAD compared with controls, and skin AF was
higher in the PAD group compared with the group with
subclinical atherosclerosis (Figure 1). Within the control group,
40 subjects had no detectable plaques and a CACS of 0 while 56
subjects had only a single plaque and/or CACS of 0–100; skin AF
did not differ between these two groups (skin AF 1.93 [1.72–2.16]
vs. 1.83 [1.67–2.05], P=0.30). Within the subclinical atheroscle-
rosis group, 17 subjects had plaques only, 10 had an increased
CACS only, and 40 had more than one plaque and increased
CACS. Between these three groups, skin AF also did not differ
(2.14 [1.74–2.45] vs.2.03 [1.80–2.23] vs. 2.16 [1.85–2.55],
P=0.47). Finally, in the PAD group, skin AF was not significantly
different between those with CACS below and those with CACS
above 100 (2.65 [2.10–3.35] vs. 2.72 [2.26–3.20], P=0.92).
The three models for ordinal regression analysis are outlined in
Table 4. The difference in skin AF between the 3 groups was
independent of age, sex, diabetes, and renal function (P=0.009).
Addition of Framingham risk score or replacement of diabetes
with metabolic syndrome in this model did not change the results
(P=0.017 and P= 0.009). In all models, the odds of having a
higher degree of atherosclerosis were 2-fold increased per unit of
skin AF.
To investigate factors associated with skin AF, univariate
correlations were calculated in the entire group. Skin AF
correlated with age (r = 0.55; P,0.001), Framingham risk score
(r = 0.35; P,0.001), diabetes (r=0.23; P,0.001), hypertension
(r = 0.19; P=0.005), body mass index (r = 0.15; P=0.02), CACS
(r=0.34; P,0.001) and systolic blood pressure (r=0.14; P=0.04),
but not with diastolic blood pressure. Skin AF also correlated with
plasma glucose (r=0.20; P=0.003), triglycerides (r=0.17;
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P=0.01), hsCRP (r=0.31; P,0.001) and inversely with LDL
(r=20.16; P=0.02). No correlations between medication and skin
AF were observed. In the linear multiple regression model, skin AF
was independently associated with age and plasma glucose (model:
R2= 0.29, P,0.001; age: standardized beta 0.46, P,0.001;
glucose: r=0.19, P=0.005). Because of the low prevalence of
diabetes, analyses were repeated after removal of the patients with
diabetes. This did not alter the results.
In the primary prevention group, skin AF also correlated with
plaque score (r=0.21; P=0.008), mean IMT of carotid and
femoral arteries (r=0.22; P= .004 and r=0.13; P=0.11) and max
IMT (r=0.26; P=0.001 and r=0.21; P=0.007), respectively. The
correlation with skin AF and CACS did not reach significance
(r = 0.13; P= 0.09).
Table 1. Clinical characteristics of study groups.
Controls
Subclinical
atherosclerosis Clinical atherosclerosis P-value
(n=96) (n=67) (n=60)
Age (years) 43.869.5 51.867.8 63.567.6 ,0.001a
Sex (Male/Female) 53/43 32/35 44/16 0.01
Skin autofluorescence (AU) 1.87 (1.68–2.12) 2.11 (1.83–2.46) 2.71 (2.15–3.27) ,0.001a
Body mass index (kg/m2) 25.0 (23.1–27.7) 26.6 (23.8–29.8) 26.3 (24.2–29.5) 0.03a
Systolic BP (mmHg) 130 (120–140) 136 (128–146) 139 (127–164) 0.005a
Diastolic BP (mmHg) 80 (73–90) 82 (75–90) 80 (75–85) 0.57
Fasting glucose (mmol/L) 5.2 (4.9–5.8) 5.3 (5.1–5.8) 5.5 (5.0–6.4) 0.09
High sensitive CRP (mg/L) 1.20 (0.60–3.00) 1.50 (0.58–3.33) 3.80 (1.35–7.10) ,0.001
Cholesterol (mmol/L) 5.7 (4.7–6.7) 6.0 (4.9–6.7) 4.3 (3.9–5.4) ,0.001
LDL-cholesterol(mmol/L) 3.8 (2.9–4.7) 4.0 (3.3–4.5) 2.5 (2.1–3.2) ,0.001
HDL-cholesterol (mmol/L) 1.3 (1.1–1.7) 1.3 (1.0–1.6) 1.3 (1.1–1.4) 0.35
Triglycerides (mmol/L) 1.36 (0.91–2.10) 1.67 (1.09–2.74) 1.69 (1.12–2.11) 0.12
Serum creatinine (umol/L) 73.5 (68.0–84.0) 70.0 (64.0–76.0) 79.0 (69.0–94.0) ,0.001a
GFR 93.7 (83.3–103.8) 96.0 (85.3–105.9) 83.1 (68.3–97.2) ,0.001
Diabetes mellitus 3 (3.1) 2 (3.0) 13 (21.7) ,0.001
Smoking 0.009
Yes 29 (30.2) 27 (40.3) 22 (36.7)
No 31 (32.3) 17 (25.4) 5 (8.3)
Past 36 (37.5) 23 (38.8) 33 (55.0)
Dyslipidaemia 77 (80.2) 59 (88.1) 51 (85.0) 0.39
Hypertension 43 (44.8) 41 (61.2) 52 (86.7) ,0.001a
Metabolic syndrome 24 (25.0) 25 (37.3) 21 (35.0) 0.19
Framingham Risk Score 2.0 (0.4–4.1) 5.1 (2.5–11.7) 9.5 (3.2–18.3) ,0.001a
aP,.05 between subclinical atherosclerosis and controls.
BP = blood pressure; GFR = glomerular filtration rate using MDRD formula.
doi:10.1371/journal.pone.0083084.t001
Table 2. Medication use of study groups.
Controls
Subclinical
atherosclerosis Clinical atherosclerosis P-value
(n=96) (n=67) (n=60)
Statin use 38 (39.6) 31 (46.3) 46 (76.7) ,0.001
Other lipid lowering medication 8 (8.3) 7 (10.4) 3 (5.0) 0.53
ACEi/ARB use 8 (8.3) 11 (16.4) 37 (61.7) ,0.001
Other antihypertensive medication 14 (14.6) 15 (22.4) 34 (56.7) ,0.001
Aspirin use 4 (4.2) 8 (11.9) 48 (80.0) ,0.001
Coumarin use 0 (0.0) 1 (1.5) 8 (13.3) ,0.001
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
doi:10.1371/journal.pone.0083084.t002
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Discussion
In the current study we demonstrate that skin AF – a non-
invasive marker for tissue AGE accumulation – is elevated in
subjects with evidence of subclinical atherosclerosis and subjects
with clinical atherosclerosis. Furthermore, skin AF increases with
the degree of atherosclerosis, independently of factors known to be
associated with accumulation of AGEs, including age, sex, diabetes
or metabolic syndrome, kidney function and Framingham risk
score.
To the best of our knowledge, this is the first study to
demonstrate an association of skin AF with varying degrees of
atherosclerosis. This was ascertained not only by measuring IMT,
but also by plaque assessment and CACS, all of which are
validated methods for measuring subclinical atherosclerosis.
Earlier, we reported that skin AF is increased and a strong
predictor of mortality in diabetes mellitus and end stage renal
disease compared with healthy controls. [8,11] Other groups have
confirmed the association between skin AGEs and coronary artery
disease in patients with type 1 diabetes, using a different setup,
referred to as skin intrinsic fluorescence. [27] The current study is
in line with these observations and presents the new finding of a
higher accumulation of AGEs in patients with subclinical
atherosclerosis, independent of diabetes and renal function, with
the simultaneous use of more than one technique [2].
In line with the hypothesis of a role of AGEs beyond diabetes
and renal disease, we demonstrated earlier that skin AF is elevated
in PAD [15,16], coronary artery disease [12] and myocardial
infarction. [13] Skin AF was shown to correlate with markers of
subclinical atherosclerosis, i.e. IMT [14,28] and small artery
elasticity [10], the soluble RAGE and with markers of inflamma-
tion, endothelial activation, and oxidative stress in other studies.
[12,13] These previous studies were all performed in populations
with known cardiovascular disease, diabetes, renal disease, or
Table 3. Classification variables for patient group definition.
Controls Subclinical atherosclerosis Clinical atherosclerosis
(n=96) (n=67) (n=60)
Calcium score (AU) 0.0 (0.0–6.9) 130.0 (0.0–248.0) 389.8 (107.6–984.0)
Mean carotid IMT 0.65 (0.57–0.74) 0.83 (0.67–0.98) NA
Max carotid IMT 0.71 (0.60–0.82) 0.97 (0.80–1.11) NA
Mean femoral IMT 0.55 (0.48–0.67) 0.70 (0.53–1.05) NA
Max femoral IMT 0.60 (0.50–0.75) 0.80 (0.63–1.25) NA
AU= arbitrary units; IMT = intima media thickness.
doi:10.1371/journal.pone.0083084.t003
Figure 1. Box plot of skin autofluorescence between patients with increasing degree of atherosclerosis.
doi:10.1371/journal.pone.0083084.g001
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autoimmune diseases. This may have confounded the relation
between skin AF and atherosclerosis. The diseases per se,
especially autoimmune diseases, could cause increases in skin
AF. [29] The study by Lutgers [14] demonstrated an association
between skin AF and IMT in healthy subjects without diabetes.
However, in this particular study plaques were not documented
and no coronary calcium score was measured. Also, a preliminary
version of the AGE-Reader was used, which has not been
developed further and was not validated to skin biopsy.
Correlations between (non-invasive) assessments for different
vascular beds i.e. IMT, carotid and coronary plaque scores, and
CACS) is moderate, even in post-mortem studies. [30] No single
method seems to adequately reflect overall atherosclerosis burden.
In line, we found only a weak concordance between the presence
of plaques and CACS, with most subjects presenting with plaques
or coronary calcifications only. This supports our choice to study
multiple vascular techniques and vascular beds. The IMT value is
strongly age dependent and a relatively weak predictor of CVD.
Therefore, we preferred to define atherosclerosis as the presence of
plaques, which is considered a more accurate surrogate for
subclinical atherosclerosis [31] and a better predictor of future
CVD. [32] Although we used the Mannheim consensus definition,
some plaques may have been missed, since we only quantified
plaques that were present at the far wall and did not scan outside
the designated segments.
CACS is a stronger predictor of future coronary events [33] and
to a lesser extent with CVD in general. CACS correlates strongly
with histopathologic coronary disease and that absence of
calcification is highly suggestive for the absence of CAD. [34]
We chose a cutoff of .100 AU for subclinical atherosclerosis,
since this is considered optimal to separate asymptomatic subjects
at high from those at low risk. Since CACS only detects the
presence of a calcified plaque, so-called ‘‘soft’’ plaques are missed.
[34] Furthermore, with the techniques we used it is not possible to
discriminate ‘‘active’’ or vulnerable from stable plaques. This
would necessitate more sophisticated and currently experimental
techniques.
Skin AF is an indirect marker for AGEs in the skin, and is
influenced by other skin fluorophores. Most AGEs are not
fluorescent. Nonetheless, in validation studies, skin AF strongly
and consistently correlated with fluorescent as well non-fluorescent
AGEs, including the major and most extensively studied AGE
N(e)-carboxymethyl-lysine. [35] We did not collect extra plasma
samples and could therefore not assess plasma AGE levels. The
disadvantage of plasma AGEs is that they can be influenced and
fluctuate due to several factors (i.e. smoking, nutrition, renal
function) whereas skin AF remains stable. Furthermore, plasma
AGE measurements have an impaired reproducibility due to a
lack of uniformity in assays, and are not independently associated
with CVD [36].
A restriction to measuring skin AF is that it could not be reliably
measured in persons with a dark skin with the AGE-Reader used
in this study. However, with the new set-up of the AGE-Reader it
is possible to perform accurate measurements in darker skin types,
even in Asian or African populations [37].
The use of cardiovascular drugs may have influenced AGE
levels. Statins and aspirin have been shown to reduce plasma levels
of the soluble receptor for AGEs. [38,39] Although no such
evidence exists for the effects on AGE levels in serum or tissue, this
cannot be excluded. If statin use would have caused mitigation of
the association between skin AF and extent of atherosclerosis (bias
toward zero), then we expect the actual relationship between skin
AF and atherosclerosis to be stronger. The majority of patients
referred for secondary prevention were treated with lipid and
blood pressure lowering drugs according to the latest guidelines,
which explains the relatively low levels of cholesterol and blood
pressure in these patients.
Since this is a cross-sectional study, a direct etiological role of
skin AF or AGEs in atherosclerosis cannot be proven. Further-
more, the relationship between skin AF and severity of athero-
sclerosis is confounded by the conventional cardiovascular risk
factors. Statistical correction inevitably results in interaction and
overadjustment, since these factors are strongly interrelated and
age dependent. Because of the small study population, we did not
correct for all risk factors separately and chose to cluster them in
the Framingham risk score and metabolic syndrome. Skin AF
should not be considered a diagnostic marker to detect (subclinical)
atherosclerosis, but as an additional non-invasive marker for
cardiovascular risk.
In conclusion, in this cross-sectional study we confirm the
hypothesis that skin AF, a non-invasive marker for AGE
accumulation, is elevated in subclinical atherosclerosis and subjects
with clinical atherosclerosis. These data add further evidence that
accumulation of AGEs is linked to atherosclerosis, even at a
subclinical level, independent of age and sex and, importantly,
diabetes and kidney disease. However, before applying this
method in clinical practice for primary prevention, these results
need conformation in a prospective cohort study.
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